Shares of Reunion Neuroscience Inc. (TSE:REUN – Get Rating) rose 4.4% during trading on Wednesday . The company traded as high as C$0.95 and last traded at C$0.95. Approximately 11,613 shares changed hands during trading, an increase of 44% from the average daily volume of 8,050 shares. The stock had previously closed at C$0.91.
Analysts Set New Price Targets
Separately, Stifel Nicolaus cut shares of Reunion Neuroscience from a “speculative buy” rating to a “hold” rating in a research note on Wednesday, March 15th.
Reunion Neuroscience Price Performance
The stock has a market capitalization of C$11.07 million, a P/E ratio of -0.15 and a beta of 4.23. The business has a fifty day moving average of C$0.99.
Reunion Neuroscience Company Profile
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.